Clinical efficacy of alendronate treatment of early-stage adult nontraumatic avascular necrosis of femoral head
10.3760/cma.j.issn.0254-9026.2011.08.013
- VernacularTitle:阿仑磷酸钠治疗早期成年非创伤性股骨头坏死的临床观察
- Author:
Shuqing CHEN
;
Baoguo SUN
;
Youjin CAI
;
Houming ZHOU
;
Jian QIN
- Publication Type:Journal Article
- Keywords:
Femur head necrosis;
Alendronate
- From:
Chinese Journal of Geriatrics
2011;30(8):661-663
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the influence of the alendronate treatment in early-stage adult nontraumatic avascular necrosis of femoral head. Methods The 83 patients with nontraumatic avascular necrosis of femoral head were enrolled in this study. They were given oral alendronate 70 mg weekly, and evaluated with Harris criteria before and after treatment. Results In the patients with ARCO Ⅰ necrosis, the scores of pain and function were higher after treatment than before [(41.45±3.55) scores vs. (38. 48± 5.55) scores, t = 3. 70, P = 0. 001; (45.06 ± 1.50) scores vs. (43.97 ±2.31) scores, t= 3.76, P= 0. 001]. In the patients with ARCO Ⅱ necrosis, the scores of pain,function and activity were also higher after treatment than before [(40. 40±4.31 ) scores vs. (37.32±6. 65) scores, t=4.06, P=0.00; (42.90±2.70) scores vs. (41.66±3.35) scores, t=3.15, P=0.003; (4.76±0.47) scores vs. (4.42±0.70) scores, t=3.35, P=0.002]. Conclusions Alendronate is effective in treatment of early-stage adult nontraumatic avascular necrosis of femoral head, in particular for ARCO Ⅱ patients. But its long-term effect is worth researching in future.